Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Study of SA030 Injection in Overweight/Obese Participants With or Without Type 2 Diabetes Mellitus (T2DM)

9. November 2026 aktualisiert von: Suzhou Siran Biotechnology Co.,Ltd.

A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SA030 Injection in Overweight/Obese Participants With or Without Type 2 Diabetes Mellitus (T2DM)

This is the first time the study drug, SA030, is being given to people. The main goal of this study is to find out if it is safe, how well people can tolerate it, how the body processes the drug, how the drug works, and whether it causes any immune reactions.

The study has two parts. In Part 1, people who are overweight or have obesity will receive a single dose of the drug, starting with a low dose and slowly increasing it. In Part 2, people with obesity (with or without type 2 diabetes) will receive multiple doses over time.

SA030 is being developed as a potential new treatment for people who are overweight or have obesity.

Over the last few decades, more and more people around the world have become overweight or obese, and the numbers keep rising in almost every country. From 1990 to 2021, this problem grew steadily and reached its highest point in 2021.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

40

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Adelaide, Australien, 5000
        • Rekrutierung
        • CMAX Clinical Research Pty Ltd North Terrace
        • Hauptermittler:
          • Dr. Thomas Polasek
    • Queensland
      • Brisbane, Queensland, Australien, 4006
        • Rekrutierung
        • Nucleus Network
        • Hauptermittler:
          • Michael Wong, Dr

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • You must be able to understand the study and sign a written consent form.
  • Men or women aged 18 to 55 years can join
  • Overweight or obese with a body mass index (BMI) between 25-40 kg/m^2(inclusive);
  • You should be generally healthy, The study doctor will check your medical history, vital signs, physical exam, blood and urine tests, Electrocardiogram, and abdominal. ultrasound. Minor issues are okay if the doctor thinks they are not medically important.
  • For female participants of childbearing potential: must be non-pregnant and non- lactating, and agree to use highly effective contraception throughout the study period;
  • For male participants of reproductive potential: must agree to use highly effective contraception during the study period to ensure effective contraception for sexual partners.

Exclusion Criteria:

  • You cannot join if you have lost or gained more than 5 percent of your body weight in the last 3 months.
  • You cannot participate if you previously had, or plan to have, weight-loss surgery or a weight-loss device during the study, except for the following procedures done more than 1 year before screening
  • Use of any over-the-counter medications, herbal supplements, or health products that may significantly affect weight or metabolism within 1 month prior to screening (e.g., orlistat, garcinia cambogia, ephedrine, etc.)
  • At screening, sitting systolic blood pressure more than of equals to 160 milli meters of mercury and/or diastolic blood pressure more than of equals to 100 mmHg, and deemed unsuitable for participation in this study by the investigator;
  • Severe psychiatric disorders or uncontrolled psychiatric conditions, including but not limited to schizophrenia, bipolar disorder, or depression, deemed unsuitable for participation in this study by the investigator;
  • If the screening ECG shows a prolonged QT/QTc interval, and a repeat test confirms QTcF greater than 450 ms in males or greater than 470 ms in females, the participant will be excluded
  • Suffering from severe diseases, including but not limited to disorders of the nervous system, cardiovascular system, hematopoietic and lymphatic system, immune system, digestive system, urinary system, respiratory system, endocrine system, and history of malignancies, which the investigator judges may compromise safety or influence study results;
  • Co-infection with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), or syphilis; or prior diagnosis of hepatitis A, D, or E without resolution;
  • Individuals who received a vaccine or live attenuated vaccine within 1 month prior to dosing, or who plan to receive a vaccine during the trial period; Major surgery within 6 months prior to screening, or planned surgery during the study period;
  • Severe infection or trauma within 4 weeks prior to screening;
  • Non-physiological blood loss more than or equals 200 milliliter within 1 month prior to study drug administration (including trauma, blood collection, or blood donation), or individuals planning to donate blood during the study period or within 60 days after dosing;
  • History of severe intolerance to subcutaneous injections (mild reactions such as local swelling or redness are permissible);
  • Individuals who have taken any prescription medication, herbal supplements, or over-the-counter drugs within 14 days prior to study drug administration;
  • Participation in other drug clinical trials within 3 months of this study's treatment initiation, or within 5 half-lives of other investigational drug exposure, or participation in siRNA or antisense oligonucleotide drug clinical trials within 6 months prior to this study's treatment initiation (participants who withdrew from the study before receiving the investigational drug may be eligible for this study);
  • Individuals who smoked more than 5 cigarettes or an equivalent amount of tobacco daily within 3 months prior to screening, or who are unable to abstain from smoking during the trial hospitalization period;
  • Weekly alcohol consumption exceeding 14 units within 3 months prior to screening (1 unit of alcohol ≈360 milli Liter beer or 45 milli Liter 40 percent alcohol spirits or 150 milli Liter wine), or those with a positive breath alcohol test on the day before dosing (breath alcohol content more than 0.0 milligram per100 mL), or those unable to abstain from alcohol during the trial hospitalization period;
  • Current or former drug users/substance abusers, or those with a positive urine drug screen on the day before dosing;
  • Other factors deemed unsuitable for trial participation by the investigator, such as potential for poor compliance.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Sequenzielle Zuweisung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Single dose escalation of SA030

single dose, 5 dose levels 1,2 3, 4 & 5

Single dose, 5 dose levels; mulitple dose, 3 dose levels or 2 dose levels

Single dose, matching placebo

Experimental: Multiple dose escalation of SA030 in obese participants

Multiple dose, 3 dose levels.

Single dose, 5 dose levels; mulitple dose, 3 dose levels or 2 dose levels

Single dose, matching placebo

Experimental: Multiple dose escalation of SA030 in obese with T2DM participants

multiple dose; 2 dose levels

Single dose, 5 dose levels; mulitple dose, 3 dose levels or 2 dose levels

Single dose, matching placebo

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Zeitfenster: Approximatly 12 months
Approximatly 12 months
Number of participants with clinical significant laboratory abnormalities
Zeitfenster: Approximatly 12 months
Approximatly 12 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in QTcF relative to baseline and relative to placebo compared to baseline
Zeitfenster: Pre-dose, multiple timepoints post-dose up to Day 5
Pre-dose, multiple timepoints post-dose up to Day 5
Peak plasma concentration (Cmax)
Zeitfenster: Pre-dose, multiple timepoints post-dose up to D5

Pharmacokinetic parameter

Pre-dose, multiple timepoints post-dose up to D5
Time to peak plasma concentration (Tmax)
Zeitfenster: Pre-dose, multiple timepoints post-dose up to Day 5

Pharmacokinetic parameter

Pre-dose, multiple timepoints post-dose up to Day 5
Plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-t)
Zeitfenster: Pre-dose, multiple timepoints post-dose up to Day 5

Pharmacokinetic parameter

Pre-dose, multiple timepoints post-dose up to Day 5
Plasma concentration-time curve from time zero extrapolated to infinity (AUC0-inf)
Zeitfenster: Pre-dose, multiple timepoints post-dose up to Day 5

Pharmacokinetic parameter

Pre-dose, multiple timepoints post-dose up to Day 5
Elimination half-life (t1/2)
Zeitfenster: Pre-dose, multiple timepoints post-dose up to Day 5

Pharmacokinetic parameter

Pre-dose, multiple timepoints post-dose up to Day 5
Terminal elimination rate constant (λz)
Zeitfenster: Pre-dose, multiple timepoints post-dose up to Day 5

Pharmacokinetic parameter:

Pre-dose, multiple timepoints post-dose up to Day 5
Apparent volume of distribution (Vd/F)
Zeitfenster: Pre-dose, multiple timepoints post-dose up to Day 5

Pharmacokinetic parameter

Pre-dose, multiple timepoints post-dose up to Day 5
Apparent clearance (CL/F)
Zeitfenster: Pre-dose, multiple timepoints post-dose up to Day 5

Pharmacokinetic parameter

Pre-dose, multiple timepoints post-dose up to Day 5
Number and percentage of participants developing immunogenicity (anti-SA030 antibodies)
Zeitfenster: Up to 12 months
Up to 12 months
Changes in weight
Zeitfenster: baseline, up to 12 months
baseline, up to 12 months
Changes in BMI
Zeitfenster: baseline, up to 12 months
baseline, up to 12 months
Changes in waist circumference
Zeitfenster: baseline, up to 12 months
baseline, up to 12 months
Changes in hip circumference,
Zeitfenster: baseline, up to 12 months
baseline, up to 12 months
Changes in waist-to-hip ratio
Zeitfenster: baseline, up to 12 months
baseline, up to 12 months
Changes in body fat content
Zeitfenster: baseline, up to 12 months
baseline, up to 12 months
Change in hepatic fat content
Zeitfenster: baseline, up to 12 months
baseline, up to 12 months
Changes in ALK7 expression
Zeitfenster: baseline, up to 12 months
baseline, up to 12 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

16. April 2026

Primärer Abschluss (Geschätzt)

24. April 2028

Studienabschluss (Geschätzt)

24. April 2028

Studienanmeldedaten

Zuerst eingereicht

11. März 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

15. März 2026

Zuerst gepostet (Tatsächlich)

18. März 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

9. November 2026

Zuletzt verifiziert

1. März 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • SAOB101-AUS

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .